Form 4: Bristol-Myers Squibb Executive Samit Hirawat Reports Stock Purchase
SEC Form 4 Filing
Samit Hirawat, EVP, Chief Medical Officer, Drug Development at Bristol-Myers Squibb, reported purchasing shares of the company's common stock on February 14, 2025.
Summary
- On February 14, 2025, Samit Hirawat, an executive at Bristol-Myers Squibb, purchased 1,823.486 shares of the company's common stock at a price of $54.84 per share.
- Following this transaction, Hirawat directly owns 63,932.486 shares of Bristol-Myers Squibb common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed as a positive sign, but the purchase is relatively small and may not be highly significant.
Positives
- An executive purchasing company stock can be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. Investors often monitor these filings for signals about management's confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of the stock purchase transaction. |
| 02/19/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, insider trading, stock purchase, Samit Hirawat, Bristol-Myers Squibb, BMY, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.